medigraphic.com

2003, Número 2

<< Anterior Siguiente >>

Cir Cir 2003; 71 (2)


Síndromes paraneoplásicos. Su asociación con el carcinoma pulmonar

Ochoa-Carrillo FJ, Chávez-Mac Gregor M, Green-Renner D, Green-Schneeweiss L

Idioma: Español
Referencias bibliográficas: 121
Paginas: 150-161
Archivo PDF: 92.98 Kb.


RESUMEN

Los síndromes paraneoplásicos son manifestaciones a distancia, sin relación con la diseminación de células tumorales, y que pueden preceder, acompañar o seguir el padecimiento neoplásico maligno. Los síndromes paraneoplásicos asociados a carcinoma pulmonar no son raros y tienen diversas manifestaciones clínicas capaces de afectar diversos órganos y sistemas de la economía. El diagnóstico de un síndrome paraneoplásico suele hacerse por exclusión, pues es indispensable descartar alteraciones sistémicas independientes o efectos asociados a la invasión tumoral. Es necesario considerar la importancia del estudio de los mecanismos y fenómenos que dan origen a estos síndromes, porque el mejor conocimiento de ellos ayudará a establecer diagnósticos más oportunos y a detectar recurrencias. En esta revisión se discuten los principales síndromes paraneoplásicos asociados a carcinoma pulmonar, así como sus mecanismos fisiopatológicos, manifestaciones clínicas, métodos diagnósticos y tratamiento..


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Registro Histopatológico de las neoplasias malignas en México, 1999 México: Dirección General de Epidemiología, Secretaría de Salud.

  2. Samet JM. The epidemiology of lung cancer. Chest 1993;103 (suppl): 20S.

  3. Marchioli CC, Graziano L. Paraneoplastic syndromes associated with small cell lung cancer. Chest Surg Clin North Am 1997;7(1):65-80.

  4. Trosseau A. Phelegmasia alba dolens. In: Clinque medicale de I´Hotel-Dieu de Paris. Vol. 3. London: New Sydenham Society; 1865. pp.695-727.

  5. Nathanson L, Hall CT. Paraneoplastic syndromes. Semin Oncol 1997;24(3):265-268.

  6. Patel MA, Davila GD, Peters GS. Paraneoplastic syndromes associated with lung cancer. Mayo Clin Proc 1993;68:278-287.

  7. De Vita VT. Cancer principles and practice of oncology. 5th ed. Philadelphia, PA, USA: JB Lippincott; 1997.

  8. Andersen HA, Prakash UB. Diagnosis of symptomatic lung cancer. Semin Respir Med 1982;3:165-175.

  9. Albertch TJ, Canada WT. Cachexia and anorexia in malignancy. Hematol Oncol Clin North Am 1996;10:791-800.

  10. Moldawer LL, Rogy MA, Lowry SF. The role of cytokines in cancer cachexia. J Parent Ent Nutr 1992;16:43S-49S.

  11. Puccio M, Nathanson L. The cancer cachexia syndrome. Semin Oncol 1997;24:266-287.

  12. Cunhba BA. Fever of unknown origin. Infec Dis Pract 1995;19:14-15.

  13. Dinarello AC, Bunn AP. Fever. Semin Oncol 1997;24:288-298.

  14. Denny-Brown D. Primary sensory neuropathy with muscular changes associated with carcinoma. J Neurol Neurosurg Psychiatry 1948;11: 73-87.

  15. Dalmau JO, Posner JB. Paraneoplastic syndromes affecting the nervous system. Semin Oncol 1997;24(3):318-328.

  16. Marchiolli CC, Graziano SL. Paraneoplastic syndromes associated with small cell lung cancer. Chest Surg Clin NA 1997;7(1):65-80.

  17. Jaeckle DE. Autoimmunity in paraneoplastic neurological syndromes: closer to the truth? Ann Neurol 1999;45(2):143-145.

  18. Darnell RB. Onconeural antigens and the paraneoplastic neurologic disorders: at the intersection of cancer, immunity and the brain. Proc Nat Acd Sci USA 1996;39:4529-4536.

  19. Dropcho EJ. Neurological paraneoplastic syndromes. J Neurol Sci 1998;153(2):264-278.

  20. Lennon VA. Paraneoplastic autoantibodies: the case for a descriptive generic nomenclature. Neurology 1994;44:2236-2240.

  21. Lang B, Vincent A. Autoimmunity to ion-channels and other proteins in paraneoplastic disorders. Curr Opin Immunol 1996;8(6):865-871.

  22. Dalmau JO, Posner JB. Paraneoplastic syndromes. Arch Neurol 1999;56:405-408.

  23. Inuzuka T. Antibodies in paraneoplastic neurological syndromes. Am J Med Sci 2000;319:217-226.

  24. Furneaux HF, Reich L, Posner JB. Autoantibody synthesis in the central nervous system of patients with paraneoplastic syndromes. Neurology 1990;40:1085-1091.

  25. Rubin DI, Kimmel DW, Cascino TL. Outcome of peroneal neuropathies in patients with systemic malignant disease. Cancer 1998;83:1602-1606.

  26. Amato AA, Sanelli PC, Anderson MP. Case records of the Massachusetts General Hospital. Case 38-2001. A 51-year-old woman with lung cancer and neuropsychiatric abnormalities. N Engl J Med 2001;345(24):1758-1765.

  27. Graus F, Bonaventura Y, Uchuya M. Indolent anti-Hu associated paraneoplastic sensory neuropathy. Neurology 1994;44:2258-2261.

  28. Hat PE, Schan F, Macsweeney E. Paraneoplastic limbic encephalitis. J Neurol Neurosurg Psychiatry 1998;64:160.

  29. Alamowitch S, Graus F, Uchuya ML. Limbic encephalitis and small cell lung cancer, clinical and immunological features. Brain 1997;120:923-928.

  30. Dropcho JE. Antiamphiphysin antibodies with small-cell lung carcinoma and paraneoplastic encephalomyelitis. Ann Neurol 1996;39:659-667.

  31. Darnell BR. The importance of defining the paraneoplastic neurologic disorders. N Engl J Med 1999;340(23):1831-1833.

  32. Sillevis SP, Grefkens J, de Leew B et al. Survival and outcome in73-anti-Hu positive patients with paraneoplastic encephalomyelitis/sensory neuronopathy. J Neurol 2002;249(6):745-753.

  33. Bachelor TT, Platten M, Hochberg FH. Immunoadsorption therapy for paraneoplastic syndromes. J Neurooncol 1998;40:131-136.

  34. Lui S, Mezrich J, Brek J. Expressions of Purkinje cell antigens in ovarian tumor and presence of anti-Purkinje cell antibodies in the serum of patients with paraneoplastic cerebellar degeneration. Neurology 1995;45(S4):A228.

  35. Dropcho EJ. Autoimmune central nervous system paraneoplastic disorders: mechanisms, diagnosis and therapeutic options. Ann Neurol 1995;37(S1):S102-S113.

  36. Saunders DB. Lambert-Eaton myasthenic syndrome: clinical diagnosis, immune mediated mechanisms, and update to therapies. Ann Neurol 1995;37(S1):S63-S73.

  37. Takamori M, Komai K, Iwasa K. Antibodies to calcium channel and synaptotagmin in Lambert-Eaton myasthenic syndrome. Am J Med Sci 2000;319:204-208.

  38. Levin KH. Paraneoplastic neuromuscular syndromes. Neurol Clin 1997;15:597-614.

  39. Salgai R, Hedges TR, Rizk M, Reimer RH, Skarin AT. Cancer-associated retinopathy in a patient with non-small-cell lung carcinoma. Lung Cancer 1998;22:149-152.

  40. Jacobson DM, Thirkill CE, Tippping SJ. A clinical triad to diagnose paraneoplastic retinopathy. Ann Neurol 1990;28:162.

  41. Kashiwabara K, Nakamura H, Kishi K, et al. Cancer-associated retinopathy during treatment for small-cell lung carcinoma. Intern Med 1999;38:597-601.

  42. Hersh B, Dalmau JO, Dangoid F. Paraneoplastic opsoclonus-myoclonus associated with anti-Hu antibody. Neurology 1994;44:1754-1755.

  43. Sabir S, James WD, Schuchter LM. Cutaneous manifestations of cancer. Curr Opin Oncol 1999;11:139-144.

  44. Carsons S. The Association of malignancy with rheumatic and connective tissue diseases. Semin Oncol 1997;24:360-372.

  45. Sridhar SS, Lobo CF, Altman RD. Clubbing in lung cancer. Chest 1998;114:1535-1537.

  46. Hojo S, Fujita J, Yamadori Y. Hepatocyte growth factor and digital clubbing. Intern Med 1997;36:44-46.

  47. Baughman RP, Cunther KL, Buchsbaum JA, Lower EE. Prevalence of diggital clubbing in bronchogenic carcinoma by a new digital index. Clin Exp Rheumatol 1998;16:21-26.

  48. Dickinson CJ. The aetiology of clubbing and hypertrophic osteoarthropathy. Eur J Clin Invest 1993;23:330-338.

  49. Farhey Y, Luggen M. Seropositive, symmetric polyarthritis in a patient with poorly differentiated lung carcinoma: carinomatous polyarthritis, hypertrophic osteoarthropathy or rheumatoid arthritis? Arthritis Care Res 1998;11:146-149.

  50. Schwartz RA. Acanthosis nigricans. J Am Acad Dermatol 1994;31:1-19.

  51. Silvestris N, Chetta G, Sasso N, Lccarelli A, Berardi T. Mucocutaneous paraneoplastic syndromes, a clinical-pathological review. J Exp Clin Cancer Res 1998;17:453-464.

  52. Cohen PR, Kurzrock R. Mucocutaneous paraneoplastic syndromes. Semin Oncol 1997;24:334-359.

  53. Drago F, Parodi A. Persistent erythema multiforme: report of two new cases and review of literature. J Am Acad Dermatol 1995;33:366-369.

  54. Lomholt H, Thertrup-Pedersen K. Paraneoplastic skin manifestations of lung cancer. Acta Dermatol Venereol 2000;80:200-202.

  55. Maoz CR, Langevitz P, Livneh A et al. High incidence of malignancies in patients with dermatomyositis and polymyositis: an 11-year analysis. Semin Arthritis Rheumatol 1998;27:319-324.

  56. Leandro MJ, Isenberg DA. Rheumatic diseases and malignancy is there an association? Scand J Rheumatol 2001;30(4):185-188.

  57. Lotti TM, Comacchi C, Ghersetich Y. Cutaneous necrotizing vasculitis. Relation with systemic disease. Adv Exp Med Biol 1999;455:115-125.

  58. Setterfield J, Shirlaw PJ, Lazarova Z, Bryant BM, Bhogal BS. Paraneoplastic cicatricial pemphigoid. Br J Dermatol 1999;141:127-131.

  59. Keffer JH. Endocrinopathy and ectopic hormones in malignancy. Hematol Oncol Clin North Am 1996;10:811-823.

  60. Odell WD. Endocrine/metabolic syndromes of cancer. Semin Oncol 1997;24:299-317.

  61. Daughaday WH, Deuel TF. Tumor secretion of growth factors. Endocrinol Metab Clin North Am 1991:20:539-547.

  62. Russell PJ, O´Mara SM, Raghavan D. Ectopic hormone production by small cell undifferentiated carcinoma. Mol Cell Endocrinol 1990;71:1-12.

  63. Barri YM, Knochel JP. Hypercalcemia and electrolyte disturbances in malignancy. Hematol Oncol Clin North Am 1996;10:775-790.

  64. Mndy GR, Guise TA. Hypercalcemia of malignancy. Am J Med 1997;103:134-141.

  65. Broadus AE, Mangin M, Ikeda K, Insogna KL, Weie EC, Burtis WJ. Humoral hypercalcemia of cancer: identification of a novel parathyroid hormone-like peptide. N Engl J Med 1988;319:556-563.

  66. Strewler GJ. The physiology of parathyroid hormone-related protein. N Engl J Med 2000;342:177-185.

  67. Bender RA, Hansen H. Hypercalcemia in bronchogenic carcinoma. Ann Intern Med 1974;80:295-308.

  68. Nishigaki Y, Ohsaki Y, Toyoshima E, Kikuchi K. Increased serum and urinary levels of parathyroid hormone-related protein COOH terminus in non-small cell lung cancer patients. Clin Cancer Res 1999;5:1473-1481.

  69. Wysolmerski JJ, Broadus AE. Hypercalcemia of malignancy: the central role of parathyroid hormone related protein. Annu Rev Med 1994;45:189-195.

  70. Brown WH. A case of pluriglandular syndrome: diabetes of bearded women. Lancet 1928;2:1022-1023.

  71. Liddle GW, Nicholson WE, Island DP. Clinical and laboratoy studies of ectopic humoral syndromes. Recent Prog Horm Res 1969;25: 283-314.

  72. Stewrt PM, Gibson S, Crosby SR. ACTH precursors characterize the ectopic ACTH syndrome. Clin Endocrinol 1994;40:199-204.

  73. Amer KM, Ibrahim NB, Forrester-Wood CP, Saad RA, Scanlon M. Lung carcinoid related Cushing’s syndrome: report of three cases and review of the literature. Postgrad Med J 2001;77(909):464-467.

  74. Dall´Asta C, Santambrogio L, Castellani M, Ambrosi B. Difficulties in diagnosis and treatment of ectopic ACTH-producing tumors of the chest. Eur J Cardiothorac Surg 2002;21(1):149-151.

  75. Lim SC, Lim HS, Tan CE, Wong ZW, Fong CM. A case report of a patient with bronchial carcinoid tumor and late presentation of Cushing’s syndrome. Ann Acad Med Singapore 1998;27:272-276.

  76. Oldfield EH. Petrosal sinus sampling with and without corticotropin releasing hormone for the differential diagnosis of Cushing’s syndrome. N Engl J Med 1992;325:897-900.

  77. Wajchenberg BL, Mendoca BB, Liberman B. Ectopic ACTH syndrome. J Steroid Biochem Mol Biol 1995;53:139-151.

  78. Delisle L, Boyer MJ, Warr D. Ectopic corticotropin syndrome and small cell carcinoma of the lung: clinical features, outcome and complications. Arch Intern Med 1993;153:746-752.

  79. Collichio FA, Woolf PD, Brower M. Management of patients with small cell lung carcinoma and the syndrome of ectopic corticotropin secretion. Cancer 1994;73:1361-1367.

  80. Schwartz WB, Bennett W, Curelop S. A syndrome of renal sodium loss and hyponatremia probably resulting from inappropriate accretion of antidiuretic hormone. Am J Med 1957;23:529-542.

  81. Shumiizu K, Nakano S, Nakano Y. Ectopic atrial natriuretic peptide production in small cell lung cancer with the syndrome of inappropriate antidiuretic hormone secretion. Cancer 1991;68:2284-2288.

  82. Gross AJ, Steinberg SM, Reilly JG. Atrial natriuretic factor and arginine vasopressin production in tumor cell lines from patients with lung cancer and their relationship to serum sodium. Cancer Res 1993;53:67-74.

  83. Shapiro J, Richardson GE. Hyponatremia of malignancy. Crit Rev Oncol Hematol 1995;18:129-135.

  84. Kumar S, Berl T. Sodium. Lancet 1998;352:220-231.

  85. Hillier TA, Abbott RD, Barrett EJ. Hyponatremia: evaluating the correction factor for hyperglycemia. Am J Med 1999;106:399-406.

  86. Grunenberger F, Bachellier P, Chenard MP et al. Hepatic and pulmonary metastases from a meningeal hemangiopericytoma and severe hypoglycemia due to abnormal secretion of insulin-like growth factor. Cancer 1999;85:2245-2248.

  87. Phillips LS, Robertson DG. Insulin-like growth factors and non-islet cell tumor hypoglycemia. Metabolism 1993;42:1093-1098.

  88. Pavelic K, Pavelic ZP, Cabrijan T, Karner I, Samarzija M, Stambrook P. Insulin-like growth factor family in malignant hemangiopericytomas: the expression and role of insulin-like growth factor I receptors. J Pathol 1999;188:69-75.

  89. Stuart CA, Prince MJ, Peters EJ. Insulin receptor proliferation: a mechanism for tumor-associated hypoglycemia. J Clin Endocrinol Metab 1986;63:879-885.

  90. Baserga R. The insulin-like growth factor I receptor: a key to tumor growth? Cancer Res 1995;55:249-252.

  91. Teale JD, Marks V. Glucocorticoid therapy suppresses abnormal secretion of big IGF-II by non-islet cell tumors inducing hypoglycemia. Clin Endocrinol 1998;49:491-498.

  92. Cai Q, Hodson SF, Kao PC. Brief report: inhibition of renal phosphate transport by a tumor product in a patient with oncogenic osteomalacia. N Engl J Med 1994;330:1679-1680.

  93. Wilkins GE, Granleese S, Hegele RG. Oncogenic osteomalacia: evidence for a humoral phosphaturic factor. J Clin Endocrinol Metab 1995;80:1628-1634.

  94. Yoshimura M. Assessment of urinary beta-core fragment of human chorionic gonadotropin as a new tumor marker of lung cancer. Cancer 1994;73:2745-2749.

  95. Walker R, Crebbin V, Stern J. Urinary gonadotropin peptide as a marker of malignancies. Anticancer Res 1994;14:1703-1710.

  96. Stenman UH, Alfthan H, Ranta T. Serum levels of human chorionic gonadotropin in non-pregnant woman and men are modulated by gonadotropin-releasin hormone and sex steroid. J Clin Endocrinol Metab 1990;71:1318-1321.

  97. Braunstein GD. Gynecomastia. N Engl J Med 1993;328:490-498.

  98. Roos BA. Plasma immunoreactive calcitonin in lung cancer. J Clin Endocrinol Metab 1980;50:659-664.

  99. Ozarda AT. Prolactin-secreting tumors. J Surg Oncol 1983;22:9-10.

  100. Melmed S. Extrapituitary acromegaly. Endocrinol Metab Clin North Am 1991;20:507-511.

  101. Galus M, Schiffman R, Olkowska D. Massive liver necrosis associated hyperamylasemia. Liver 1998;18:205-207.

  102. Boskir A, Simsek B, Güngört A, Torun M. Ascorbic acid and uric acid in lung cancer patients. J Clin Pharm Ther 1999;24:43-47.

  103. Frenkel EP, Bick RL, Rutherford CJ. Anemia of malignancy. Hematol Oncol Clin North Am 1996;10:861-873.

  104. Staszewski H. Hematological paraneoplastic syndromes. Semin Oncol 1997;24:329-333.

  105. Ulvestad E, Berentsen S, Shammas FV. Clinical immunology of agglutinin disease. J Haematol 1999;63:259-266.

  106. Dunphy CH, Batanian JR. Biphenotypic hematological malignancy with T-lymphoid and myeloid differentiation: association with t(3;12) (p25;q24.3). Case report and review of literature. Cancer Genet Cytogenet 1999;114:51-57.

  107. Kato N, Yasukawa K, Onozuka T, Kimura K. Paraneoplastic syndromes of leukocytosis, thrombocytosis, and hypercalcemia associated with squamous cell carcinoma. J Dermatol 1999;26:352-358.

  108. Emmanouilides C, Glaspy J. Opportunistic infections in oncologic patients. Hematol Oncol Clin North Am 1996;10:841-860.

  109. Gordon LI, Kwaan HC. Thrombotic microangiopathy manifesting as thrombotic thrombocytopenic purpura/hemolytic uremic syndrome in the cancer patient. Semin Thromb Hemost 1999;25:217-221.

  110. Estrov Z, Talpaz M, Maligit G. Elevated plasma thrombopoietin activity in patients with related thrombocytosis. Am J Med 1998;98:551-558.

  111. Morrisin M. An analysis of the blood picture in 100 cases of malignancy. J Lab Clin Med 1932;17:1071-1078.

  112. Bick RL. Alterations of hemostasis in malignancy. In: Bick RL, Bennett JM, Brynes RK (editors). Hematology: clinical and laboratory practice. St. Louis, MO, USA: C.V. Mosby 1993.

  113. Bick RL, Strauss JF, Frenkel EP. Thrombosis and hemorrhage in oncology patients. Hematol Oncol Clin North Am 1996;4:875-907.

  114. Bick RL. Disseminated intravascular coagulation: objective clinical and laboratory diagnosis, treatment and assessment of therapeutic response. Semin Thromb Haemost 1996;22:69-81.

  115. Bick RL, Baker WF. Disseminated intravascular coagulation syndromes. Hematol Pathol 1992;6:1-13.

  116. Kazmers A, Groehn H, Meeker C. Acute calf vein thrombosis: outcomes and implications. Am Surg 1999;65:1124-1128.

  117. Monreal M, Prandoni P. Venous thromboembolism as first manifestation of cancer. Semin Thromb Haemost 1999;25:131-136.

  118. Girolami A, Prandoni P, Bagatella P, Girolami B. Venous thromboses of upper limbs are more frequently associated with occult cancer as compared with those of lower limbs. Blood Coagul Fibrinol 1999;10:455-457.

  119. Maesaka JK, Mittal SK, Fishbane S. Paraneoplastic syndromes of the kidney. Semin Oncol 1997;24:373-381.

  120. Alpers C. Glomerulopathies of dysproteinemias, abnormal immunoglobulin deposition and lymphoproliferative disorders. Curr Opin Nephrol 1994;3:349-355.

  121. Usalan C, Emri S. Membranoproliferaive glomerulonephritis associated with small cell lung carcinoma. Int Urol Nephrol 1998;30: 209-213.




2020     |     www.medigraphic.com